Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics

Madrigal Pharmaceuticals, Inc. (MDGL): $269.20

-7.28 (-2.63%)

POWR Rating

Component Grades








Add MDGL to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




#114 of 168

in industry

MDGL Price/Volume Stats

Current price $269.20 52-week high $322.67
Prev. close $276.48 52-week low $57.21
Day low $268.50 Volume 235,221
Day high $280.52 Avg. volume 381,426
50-day MA $277.45 Dividend yield N/A
200-day MA $190.58 Market Cap 4.92B

MDGL Stock Price Chart Interactive Chart >

Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.

MDGL Latest News Stream

Event/Time News Detail
Loading, please wait...

MDGL Latest Social Stream

Loading social stream, please wait...

View Full MDGL Social Stream

Latest MDGL News From Around the Web

Below are the latest news stories about MADRIGAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MDGL as an investment opportunity.

Madrigal Pharmaceuticals Supports International NASH Day on June 8

Company expands support for NASH disease education through patient advocacy partnerships and a new digital campaign for patients with at-risk NASHCONSHOHOCKEN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced its support for the sixth International NASH Day, taking place on June 8, 2023. Led by the Global Liver Institute (GLI) in part

Yahoo | June 6, 2023

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at two upcoming investor conferences: Jefferies Healthcare Conference2:30 pm ET on Wednesday, June 7, 2023. Goldman Sachs Global Healthcare Conference 12:20 pm ET on Tuesday, June 13, 2023. The fireside chats will be

Yahoo | June 1, 2023

Why Madrigal Pharmaceuticals Stock Is Marching Higher Today

Shares of the clinical-stage drugmaker Madrigal Pharmaceuticals (NASDAQ: MDGL) were up by 6.2% on elevated volume as of 12:16 p.m. ET Wednesday. The biotech appears to be benefiting from two key tailwinds. First, a Food and Drug Administration (FDA) panel voted overwhelmingly last Friday against approving Intercept Pharmaceuticals' (NASDAQ: ICPT) candidate, obeticholic acid, for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).

Yahoo | May 24, 2023

Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days

Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients.

Yahoo | May 24, 2023

Intercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation

Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.

Yahoo | May 22, 2023

Read More 'MDGL' Stories Here

MDGL Price Returns

1-mo -10.16%
3-mo 11.41%
6-mo 302.33%
1-year 262.31%
3-year 132.77%
5-year -4.86%
YTD -7.25%
2022 242.52%
2021 -23.77%
2020 22.02%
2019 -19.17%
2018 22.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!